

Maarten Boers

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5731082/maarten-boers-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

293 papers	20,199 citations	57 h-index	140 g-index
344 ext. papers	24,027 ext. citations	4.1 avg, IF	6.29 L-index

#	Paper	IF	Citations
293	American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995 , 38, 727-35		2250
292	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974	7.4	1649
291	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	7.4	1487
290	The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. <i>Arthritis and Rheumatism</i> , 1993 , 36, 729-40		1228
289	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	7.4	851
288	Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. <i>Lancet, The</i> , 1997 , 350, 309-18	4.0	801
287	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 573-86		520
286	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
285	Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 745-53	5.7	508
284	Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. <i>Journal of Rheumatology</i> , 1997 , 24, 799-802	4.1	474
283	How to select outcome measurement instruments for outcomes included in a "Core Outcome Set" - a practical guideline. <i>Trials</i> , 2016 , 17, 449	2.8	420
282	COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. <i>Arthritis and Rheumatism</i> , 2002 , 46, 347-56		400
281	OMERACT: an international initiative to improve outcome measurement in rheumatology. <i>Trials</i> , 2007 , 8, 38	2.8	324
280	Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 285-93	2.4	319
279	Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. <i>Arthritis and Rheumatism</i> , 2004 , 50, 36-42		295
278	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002 , 61, 718-22	2.4	284
277	Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1571-9		271

276	EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1560-7	2.4	254
275	Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1395-400	2.4	247
274	Core outcome domains for clinical trials in non-specific low back pain. <i>European Spine Journal</i> , 2015 , 24, 1127-42	2.7	193
273	Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 842-5	2.4	191
272	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1371-7		159
271	Core outcome measurement instruments for clinical trials in nonspecific low back pain. <i>Pain</i> , 2018 , 159, 481-495	8	156
270	EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1905-13	2.4	155
269	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 952-7	2.4	153
268	Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012 , 67, 1111-7	9.3	137
267	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1360-4	2.4	132
266	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 204-10	2.4	125
265	Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1913-9	2.4	125
264	Outcomes from the Patient Perspective Workshop at OMERACT 6. <i>Journal of Rheumatology</i> , 2003 , 30, 868-72	4.1	122
263	Effects of glucocorticoids on radiological progression in rheumatoid arthritis. <i>The Cochrane Library</i> , 2007 , CD006356	5.2	118
262	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005 , 32, 2016-24	4.1	116
261	Outcome measures in rheumatoid arthritis randomised trials over the last 50 years. <i>Trials</i> , 2013 , 14, 324	2.8	113
260	Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. <i>Arthritis and Rheumatism</i> , 2002 , 46, 913-20		111
259	World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. <i>Journal of rheumatology Supplement, The</i> , 1994 , 41, 86-9		108

258	Measurement Properties of Visual Analogue Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. <i>Journal of Pain</i> , 2019 , 20, 245-263	5.2	99
257	Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1582-7	2.4	96
256	Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 637-41	2.4	90
255	Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 571-4	2.4	88
254	Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1015-21	2.4	85
253	Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1734-9		80
252	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 807-12	2.4	77
251	OMERACT conference on outcome measures in rheumatoid arthritis clinical trials: introduction. <i>Journal of Rheumatology</i> , 1993 , 20, 528-30	4.1	77
250	A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1071-8	2.4	74
249	Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. OMERACT Committee. <i>Journal of Rheumatology</i> , 1993 , 20, 555-6	4.1	74
248	How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. <i>Journal of Rheumatology</i> , 2014 , 41, 1025-30	4.1	72
247	Dutch-Flemish translation of 17 item banks from the patient-reported outcomes measurement information system (PROMIS). <i>Quality of Life Research</i> , 2014 , 23, 1733-41	3.7	72
246	Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. <i>Aging Clinical and Experimental Research</i> , 2016 , 28, 47-58	4.8	69
245	Combination therapy in rheumatoid arthritis: updated systematic review. <i>Rheumatology</i> , 1998 , 37, 612-9	3.9	65
244	The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1004-10	2.4	62
243	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3850-5		61
242	Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2242-6		61
241	Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. <i>Arthritis and Rheumatism</i> , 2009 , 61, 704-10		60

240	Serum 14-3-3 is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2104-13	4.1	59
239	Evidence for predictive validity of remission on long-term outcome in rheumatoid arthritis: a systematic review. <i>Arthritis Care and Research</i> , 2010 , 62, 108-17	4.7	56
238	A systematic review highlights the need to investigate the content validity of patient-reported outcome measures for physical functioning in patients with low back pain. <i>Journal of Clinical Epidemiology</i> , 2018 , 95, 73-93	5.7	55
237	Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1763-9	2.4	54
236	Repair of erosions in rheumatoid arthritis does occur. Results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. <i>Journal of Rheumatology</i> , 2003 , 30, 1102-7	4.1	53
235	Report from the OMERACT Hand Osteoarthritis Working Group: Set of Core Domains and Preliminary Set of Instruments for Use in Clinical Trials and Observational Studies. <i>Journal of Rheumatology</i> , 2015 , 42, 2190-7	4.1	48
234	Updating the OMERACT filter: implications for patient-reported outcomes. <i>Journal of Rheumatology</i> , 2014 , 41, 1011-5	4.1	48
233	COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. <i>BMC Medical Research Methodology</i> , 2020 , 20, 293	4.7	48
232	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019 , 46, 1021-1027	4.1	47
231	NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. <i>Lancet, The</i> , 2001 , 357, 1222-3	4.0	47
230	Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1233-40	2.4	45
229	Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. <i>Rheumatology</i> , 2018 , 57, 555-562	3.9	44
228	Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 484-487	2.4	44
227	Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: results from the APPRAISE study. <i>RMD Open</i> , 2016 , 2, e000237	5.9	44
226	Minimal clinically important difference module: summary, recommendations, and research agenda. <i>Journal of Rheumatology</i> , 2001 , 28, 452-4	4.1	43
225	Core outcome sets for research and clinical practice. <i>Brazilian Journal of Physical Therapy</i> , 2017 , 21, 77-84	3.7	42
224	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). <i>British Journal of Dermatology</i> , 2018 , 178, e332-e341	4.1	42
223	Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 675-81	2.4	41

222	Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. <i>Lancet Rheumatology, The</i> , 2021 , 3, e778-e788	14.2	40
221	Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets. <i>Journal of Rheumatology</i> , 2014 , 41, 986-93	4.1	39
220	Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11. <i>Journal of Rheumatology</i> , 2014 , 41, 978-85	4.1	36
219	A core outcome set for clinical trials on non-specific low back pain: study protocol for the development of a core domain set. <i>Trials</i> , 2014 , 15, 511	2.8	36
218	A prospective cohort study of 14-3-3 ⁺ ACPA and/or RF-positive patients with arthralgia. <i>Arthritis Research and Therapy</i> , 2016 , 18, 76	5.7	35
217	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019 , 46, 1028-1035	4.1	33
216	Chronological reading of radiographs in rheumatoid arthritis increases efficiency and does not lead to bias. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 391-5	2.4	33
215	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 981-989	4.1	33
214	Evidence on the measurement properties of health-related quality of life instruments is largely missing in patients with low back pain: A systematic review. <i>Journal of Clinical Epidemiology</i> , 2018 , 102, 23-37	5.7	32
213	Minimal clinically important difference in radiological progression of joint damage over 1 year in rheumatoid arthritis: preliminary results of a validation study with clinical experts. <i>Journal of Rheumatology</i> , 2001 , 28, 904-10	4.1	32
212	Patient-reported outcomes in core domain sets for rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 705-12	8.1	31
211	Cohort Profile: Cohort Hip and Cohort Knee (CHECK) study. <i>International Journal of Epidemiology</i> , 2016 , 45, 36-44	7.8	31
210	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017 , 10, 141-152	3.7	31
209	Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 266	5.7	31
208	Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. <i>PLoS ONE</i> , 2014 , 9, e87965	3.7	31
207	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019 , 46, 1014-1020	4.1	30
206	Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard?. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1481-3		30
205	Scope for improvement in the quality of reporting of systematic reviews. From the Cochrane Musculoskeletal Group. <i>Journal of Rheumatology</i> , 2006 , 33, 9-15	4.1	30

204	"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017 , 69, 1134-1141	4.7	29
203	Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. <i>Journal of Rheumatology</i> , 2014 , 41, 1000-4	4.1	28
202	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
201	The COBRA trial 20 years later. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S46-51	2.2	27
200	Calibration and Validation of the Dutch-Flemish PROMIS Pain Interference Item Bank in Patients with Chronic Pain. <i>PLoS ONE</i> , 2015 , 10, e0134094	3.7	25
199	Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 586-589	2.4	24
198	14-3-3 Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 1587-94	4.1	24
197	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018 , 19, 67	2.8	24
196	Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 33-7	2.4	24
195	The Dutch-Flemish PROMIS Physical Function item bank exhibited strong psychometric properties in patients with chronic pain. <i>Journal of Clinical Epidemiology</i> , 2017 , 87, 47-58	5.7	23
194	Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. <i>Rheumatology</i> , 2001 , 40, 1231-7	3.9	23
193	Patients with rheumatic diseases adhere to COVID-19 isolation measures more strictly than the general population. <i>Lancet Rheumatology, The</i> , 2020 , 2, e583-e585	14.2	23
192	Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	22
191	A New Concept of Health Can Improve the Definition of Frailty. <i>Calcified Tissue International</i> , 2015 , 97, 429-31	3.9	22
190	Measurement of stiffness in patients with rheumatoid arthritis in low disease activity or remission: a systematic review. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 28	2.8	22
189	A reference case for economic evaluations in osteoarthritis: an expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 44, 271-82	5.3	22
188	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016 , 43, 182-6	4.1	21
187	Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2145-52	4.1	21

186	A first step to assess harm and benefit in clinical trials in one scale. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 627-32	5.7	21
185	OMERACT: an international initiative to improve outcome measurement in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2005 , 23, S10-3	2.2	21
184	Is it time to revisit the role of ultrasound in rheumatoid arthritis management?. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 7-8	2.4	19
183	Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. <i>Rheumatology</i> , 2017 , 56, 1472-1478	3.9	19
182	An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 581-590	4.1	19
181	Updating the OMERACT filter: core areas as a basis for defining core outcome sets. <i>Journal of Rheumatology</i> , 2014 , 41, 994-9	4.1	19
180	Validation of two PROMIS item banks for measuring social participation in the Dutch general population. <i>Quality of Life Research</i> , 2019 , 28, 211-220	3.7	19
179	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015 , 42, 2204-9	4.1	18
178	Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12. <i>Journal of Rheumatology</i> , 2016 , 43, 203-7	4.1	18
177	Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also 'disconnect' disease activity and damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 406-9	2.4	18
176	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2021 , 185, 139-146	4	18
175	Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures. <i>Rheumatology</i> , 2015 , 54, 2221-9	3.9	17
174	Updating the OMERACT filter at OMERACT 11. <i>Journal of Rheumatology</i> , 2014 , 41, 975-7	4.1	17
173	Impact of quality items on study outcome. Treatments in acute lateral ankle sprains. <i>International Journal of Technology Assessment in Health Care</i> , 2000 , 16, 1136-46	1.8	17
172	Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2955-2963	5.6	17
171	Calibration of the Dutch-Flemish PROMIS Pain Behavior item bank in patients with chronic pain. <i>European Journal of Pain</i> , 2016 , 20, 284-96	3.7	17
170	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1268-71	2.4	17
169	Effectiveness of an (18)F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016 , 118, 251-6	5.3	16

168	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 699-708	5.3	16
167	Value of autopsy in internal medicine: a 1-year prospective study of hospital deaths. <i>European Journal of Clinical Investigation</i> , 1988 , 18, 314-20	4.6	16
166	Graphics and statistics for cardiology: designing effective tables for presentation and publication. <i>Heart</i> , 2018 , 104, 192-200	5.1	16
165	The OMERACT Stepwise Approach to Select and Develop Imaging Outcome Measurement Instruments: The Musculoskeletal Ultrasound Example. <i>Journal of Rheumatology</i> , 2019 , 46, 1394-1400	4.1	15
164	A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2013 , 52, 1435-7	3.9	15
163	Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective. <i>Journal of Rheumatology</i> , 2015 , 42, 1971-1975	4.1	14
162	Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 228	5.7	14
161	Updating the OMERACT filter: discrimination and feasibility. <i>Journal of Rheumatology</i> , 2014 , 41, 1005-10	4.1	14
160	Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2703-4		14
159	Feasibility of Self-Monitoring Rheumatoid Arthritis With a Smartphone App: Results of Two Mixed-Methods Pilot Studies. <i>JMIR Formative Research</i> , 2020 , 4, e20165	2.5	13
158	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1889-1893	4.1	12
157	Updated Consolidated Standards of Reporting Trials (CONSORT): it just gets better. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 813-4	5.7	12
156	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. <i>Current Medical Research and Opinion</i> , 2011 , 27, 315-25	2.5	12
155	Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis: argument in opposition. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1642-5		12
154	Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients. <i>Transplantation Proceedings</i> , 1988 , 20, 371-5	1.1	12
153	Outcome measures for adherence data from a medication event monitoring system: A literature review. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019 , 44, 1-5	2.2	12
152	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. <i>Journal of Rheumatology</i> , 2019 , 46, 976-980	4.1	11
151	Updating the OMERACT filter: implications for imaging and soluble biomarkers. <i>Journal of Rheumatology</i> , 2014 , 41, 1016-24	4.1	11

150	The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 186-92	2.4	11
149	Cardiovascular Event Risk in Rheumatoid Arthritis Compared with Type 2 Diabetes: A 15-year Longitudinal Study. <i>Journal of Rheumatology</i> , 2020 , 47, 316-324	4.1	11
148	The short-term effects of two high-dose, step-down prednisolone regimens on body composition in early rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1615-22	3.9	10
147	Rheumatoid arthritis: Remission - keeping the patient experience front and centre. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 573-574	8.1	10
146	Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial. <i>Rheumatology</i> , 2017 , 56, 1586-1596	3.9	10
145	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017 , 44, 1916-1919	4.1	10
144	A new design for registration trials in rheumatoid arthritis allowing secondary head-to-head comparisons with standard of care treatment including biologicals. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 4-6	2.4	10
143	Cyclosporine nephrotoxicity in rheumatoid arthritis: no effect of short term misoprostol treatment. <i>Journal of Rheumatology</i> , 1992 , 19, 534-7	4.1	10
142	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 840-847	2.4	10
141	Clinical measures in rheumatoid arthritis: which are most useful in assessing patients?. <i>Journal of Rheumatology</i> , 1994 , 21, 1773-4	4.1	9
140	The validity of radiography as outcome measure in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 1995 , 22, 1783-6	4.1	9
139	A Smartphone App for Self-Monitoring of Rheumatoid Arthritis Disease Activity to Assist Patient-Initiated Care: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e15105	10.5	9
138	Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 983-989	5.3	9
137	An Algorithm for the Diagnosis of Behçet Disease Uveitis in Adults. <i>Ocular Immunology and Inflammation</i> , 2020 , 1-10	2.8	9
136	What Is the Relationship Between Morning Symptoms and Measures of Disease Activity in Patients With Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2015 , 67, 1202-1209	4.7	8
135	RAID: a valid tool to quantify the impact of rheumatoid arthritis. But what impact will it have on the core set for trials?. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 884-5	2.4	8
134	One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy. <i>RMD Open</i> , 2016 , 2, e000313	5.9	8
133	Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent -mediated Paget's disease of bone. <i>BMJ Open</i> , 2019 , 9, e030689	3	8

132	Studying the benefit/risk ratio of glucocorticoids in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2007 , 34, 661-3	4.1	8
131	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019 , 46, 1159-1163	4.1	7
130	Content validity of the Dutch Rheumatoid Arthritis Impact of Disease (RAID) score: results of focus group discussions in established rheumatoid arthritis patients and comparison with the International Classification of Functioning, Disability and Health core set for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 22	5.7	7
129	Safety of Abatacept Versus Placebo in Rheumatoid Arthritis: Integrated Data Analysis of Nine Clinical Trials. <i>ACR Open Rheumatology</i> , 2019 , 1, 251-257	3.5	7
128	Cross-Cultural and Construct Validity of the Animated Activity Questionnaire. <i>Arthritis Care and Research</i> , 2017 , 69, 1349-1359	4.7	7
127	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. <i>Arthritis Care and Research</i> , 2017 , 69, 989-996	4.7	7
126	Biological treatment in rheumatoid arthritis: when to stop?. <i>Lancet, The</i> , 2014 , 383, 288-9	4.0	6
125	Prevention or retardation of joint damage in rheumatoid arthritis: issues of definition, evaluation and interpretation of plain radiographs. <i>Drugs</i> , 2002 , 62, 1717-24	12.1	6
124	Trilateral retinoblastoma: is the location of the intracranial tumor important?. <i>Cancer</i> , 2000 , 88, 965-7	6.4	6
123	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020 , 22, 177	5.7	6
122	Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STATins to Prevent Rheumatoid Arthritis (STAPRA) trial. <i>RMD Open</i> , 2021 , 7,	5.9	6
121	Patient-reported outcomes 2019 , 479-492		5
120	A new graph and scoring system simplified analysis of changing states: disease remissions in a rheumatoid arthritis clinical trial. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 633-7	5.7	5
119	Standing on the promises: first wave validation reports of the Patient-Reported Outcome Measurement Information System. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1167-8	5.7	5
118	How to ascertain drug safety in the context of benefit. Controversies and concerns. <i>Journal of Rheumatology</i> , 2009 , 36, 2114-21	4.1	5
117	Relapse-remission and remission-relapse switches in rheumatoid arthritis patients were modeled by random effects. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 1085-94	5.7	5
116	Non-overlapping American College of Rheumatology response rates: a better way to report response in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3524-7		5
115	Outcome measures in rheumatoid arthritis: the OMERACT process. <i>Expert Review of Clinical Immunology</i> , 2007 , 3, 271-5	5.1	5

114	Glucocorticoids in rheumatoid arthritis: a senescent research agenda on the brink of rejuvenation?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004 , 18, 21-9	5.3	5
113	Null bar and null zone are better than the error bar to compare group means in graphs. <i>Journal of Clinical Epidemiology</i> , 2004 , 57, 712-5	5.7	5
112	PROMIS Physical Function Short Forms Display Item- and Scale-Level Characteristics at Least as Good as the Roland Morris Disability Questionnaire in Patients With Chronic Low Back Pain. <i>Archives of Physical Medicine and Rehabilitation</i> , 2020 , 101, 297-308	2.8	5
111	First Validation of the Full PROMIS Pain Interference and Pain Behavior Item Banks in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1550-1559	4.7	5
110	Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e68	2.4	5
109	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 242-249	2.4	5
108	Designing effective graphs to get your message across. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 833-839	2.4	5
107	Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. <i>Journal of Rheumatology</i> , 2019 , 46, 1406-1408	4.1	4
106	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020 , 47, 1379-1384	4.1	4
105	Higher body mass index is associated with lower foot health in patients with rheumatoid arthritis: baseline results of the Amsterdam-Foot cohort. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 186-194	1.9	4
104	Progress towards optimal trial end-points in rheumatoid arthritis. <i>BioDrugs</i> , 1997 , 7, 40-50	7.9	4
103	Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting. <i>British Journal of Dermatology</i> , 2020 , 185, 139	4	4
102	Response to: 'Let's not fool ourselves. In RA, the ACR/EULAR remission criteria are not perfect!' by Baker. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e13	2.4	3
101	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019 , 46, 1173-1178	4.1	3
100	Assessment of Health Outcomes 2017 , 496-508		3
99	OP0151 Cobra-light therapy is clinically non-inferior to original cobra therapy in the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 104.3-105	2.4	3
98	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. <i>RMD Open</i> , 2017 , 3, e000502	5.9	3
97	Further Simplification of the Simple Erosion Narrowing Score With Item Response Theory Methodology. <i>Arthritis Care and Research</i> , 2016 , 68, 1206-10	4.7	3

96	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016 , 43, 1024-6	4.1	3
95	Patients' and rheumatologists' perspectives on the efficacy and safety of low-dose glucocorticoids in rheumatoid arthritis-an international survey within the GLORIA study. <i>Rheumatology</i> , 2021 , 60, 3334-3342	3.9	3
94	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1125-1133	5.3	3
93	Prevalence and validity of ACR/EULAR remission in four European early rheumatoid arthritis cohorts. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 362-370	2.2	3
92	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1269-1276	2.4	2
91	Excessive Pricing Causes Poor Access to Biologics. <i>Journal of Rheumatology</i> , 2018 , 45, 876	4.1	2
90	OP0276 Risk of Serious Adverse Effects Associated with Different Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomised Trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1762-177	2.4	2
89	THU0244 14-3-3Eta is an Independent Predictor of Radiographic Changes in Early RA and Higher Titres Inform A Higher Likelihood of Joint Damage Progression. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 266.2-266	2.4	2
88	THU0154 Adverse effects of glucocorticoid therapy in rheumatoid arthritis (RA): A systematic review and meta-analysis of randomized controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 207.3-208	2.4	2
87	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. <i>Drug Information Journal</i> , 2006 , 40, 111-116		2
86	Combination treatment in autoimmune diseases. Methodology of combination trials. <i>Seminars in Immunopathology</i> , 2001 , 23, 27-33		2
85	.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkab089	1.1	2
84	Assessment of Health Outcomes 2013 , 462-475.e3		2
83	The Added Value of Radiographs in Diagnosing Knee Osteoarthritis Is Similar for General Practitioners and Secondary Care Physicians; Data from the CHECK Early Osteoarthritis Cohort. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
82	P187 Secukinumab significantly decreased joint synovitis measured by Power Doppler ultrasonography in biologic-naïve patients with active psoriatic arthritis: primary (12week) results from a randomised, placebo-controlled Phase 3 study. <i>Rheumatology</i> , 2021 , 60,	3.9	2
81	EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1116-1123	2.4	2
80	Dutch reference values for the Patient-Reported Outcomes Measurement Information System Scale v1.2 - Global Health (PROMIS-GH). <i>Journal of Patient-Reported Outcomes</i> , 2021 , 5, 38	2.6	2
79	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 601-606	5.3	2

78	Barriers and potential solutions in the recruitment and retention of older patients in clinical trials-lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021 , 50, 1988-1996	3	2
77	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1108-1112	5.3	2
76	Postmenopausal Osteoporosis183-242		2
75	Progress toward the development of a new definition of remission in rheumatoid arthritis. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2010 , 68, 140-2		2
74	Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1400-1405	5.3	1
73	The controversy of using PGA to define remission in RA. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 245	8.1	1
72	SAT0037 Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 602.1-602	2.4	1
71	"Spydergrams" to depict the results of the Short Form-36 questionnaire: a work in progress. <i>Journal of Clinical Epidemiology</i> , 2013 , 66, 243-6	5.7	1
70	The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A5.1-A5	2.4	1
69	Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies. <i>Disease Management and Health Outcomes</i> , 2000 , 8, 87-97		1
68	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology41-62		1
67	Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine. <i>RMD Open</i> , 2021 , 7,	5.9	1
66	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 607-617	5.3	1
65	Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1360-1360 ¹	5.3	1
64	Systematic review of rheumatoid arthritis clinical studies: Suboptimal statistical analysis of radiological data. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 218-221	5.3	1
63	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3B Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 319-322	4.7	1
62	Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta-Regression Analyses. <i>Arthritis Care and Research</i> , 2020 , 72, 1490-1496	4.7	1
61	Effects of Co-medication with Glucocorticoids in Biologics Trials. <i>Journal of Rheumatology</i> , 2018 , 45, 1605.1	4.1	1

60	Diagnosis of early stage knee osteoarthritis based on early clinical course: data from the CHECK cohort. <i>Arthritis Research and Therapy</i> , 2021 , 23, 217	5.7	1
59	Response to Secukinumab on Synovitis using Power Doppler Ultrasound in Psoriatic Arthritis: 12-week Results from a Phase III Study, ULTIMATE. <i>Rheumatology</i> , 2021 ,	3.9	1
58	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1139-1145	5.3	1
57	Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial. <i>Osteoporosis International</i> , 2021 , 32, 1441-1449	5.3	1
56	SAT0551 WHOLE BODY MACROPHAGE PET IMAGING THAT INCLUDES THE FEET CAN PROVIDE ADDITIONAL INFORMATION TO CLINICAL ASSESSMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1233.2-1233	2.4	0
55	Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 301-302	2.4	0
54	Long-term Glucocorticoid Use in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1342	4.1	0
53	Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count. <i>Rheumatology</i> , 2021 , 60, 5239-5246	3.9	0
52	Diagnosis for early stage knee osteoarthritis: probability stratification, internal and external validation; data from the CHECK and OAI cohorts.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152007	5.3	0
51	The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
50	SAT0620 Validation of The Dutch-Flemish Promis Fatigue Item Bank in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 894.2-894	2.4	
49	Public/private partnerships, at what price?. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	
48	THU0104 Limited Safety Signals, but No Advantage of Cobra-Light over Cobra Combination Therapy 4 Years after Initiation of The Cobra-Light Trial in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 217.1-217	2.4	
47	FRI0229 Risk of Hospitalized Infections in Patients with Rheumatoid Arthritis Initiating Abatacept and Other Biologics: Analysis of A United States Claims Database. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 516.1-516	2.4	
46	THU0064 Short and Sustained Periods of ACR/EULAR Remission Predict Good Functional Outcome, but Not Stable Radiographic Outcome in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 201.1-201	2.4	
45	OP0106 Change in Bone Mineral Density with High-Dose Prednisone in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 95.1-95	2.4	
44	THU0635 Defining The Optimal Biological Monotherapy in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis of Randomised Trials. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 423.3-424	2.4	
43	THU0062 Prognosis of Early Rheumatoid Arthritis Patients with Erosive Disease at Baseline. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 200.2-200	2.4	

42	THU0563 Validation of the Dutch-Flemish PROMIS Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 377.2-377	2.4
41	THU0564 Validation of the Dutch-Flemish PROMIS Physical Functioning Item Bank in Patients with Chronic Pain. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 377.3-378	2.4
40	SAT0051 Alternative Ways to Analyze Remission: Applying the Conrew Score and Patient Vector Graph to Camera Trial II Data. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 607.3-608	2.4
39	FRI0224 A New Method to Assess Activity Limitations in Patients with Hip and Knee Osteoarthritis: the Animated Activity Questionnaire (AAQ): Part 1. Development, Validity and Reliability. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 463.3-464	2.4
38	AB0466 Glucocorticoid Effect on Radiographic Progression in Rheumatoid Arthritis BIOLOGICS Trials. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 961.4-962	2.4
37	OP0202 Omeract Method of Combined Reporting of Benefit and Harm Applied to the TEAR Trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 139.1-139	2.4
36	THU0599 Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 418.1-418	2.4
35	OP0013 Effective Treatment Rapidly Improves both Disease Activity and Physical Activity in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 69.1-69	2.4
34	Alternative Ways to Quantify Sustained Remission: Applying the Continuity Rewarded Score and Patient Vector Graph. <i>Arthritis Care and Research</i> , 2015 , 67, 1471-4	4.7
33	OP0314 Is Cardiovascular Risk Management in Patients with Rheumatoid Arthritis Effective? Two Year Follow Up Reveals Unexpected Rise in Cardiovascular Risk!. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 192.1-192	2.4
32	AB0779 7 Years of Follow-Up of Early Symptomatic Oa: Characteristics of CHECK (Cohort HIP & Cohort Knee). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1062.1-1062	2.4
31	SAT0531 Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A761.2-A761	2.4
30	AB1360 Gastrointestinal events in patients receiving NSAIDs for rheumatic diseases in routine practice: The pan-european evidence study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 715.13-715	2.4
29	AB0306 The influence of the definition of patient global assessment in assessment of ACR/eular remission and minimal disease activity in rheumatoid arthritis: A 3-month cohort study in patients starting etanercept. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 655.2-655	2.4
28	FRI0521 A framework and process to develop core outcome measurement sets for clinical trials in rheumatology: omeract filter 2.0. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A550.3-A551	2.4
27	SAT0130 Defining the Optimal Biological Monotherapy in Rheumatoid Arthritis (RA): Network Meta-Analysis of Randomized Trials. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A625.1-A625	2.4
26	AB0184 Applying the conrew score to camera -trial ii data. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A842.1-A842	2.4
25	THU0045 Score and framingham predict cv disease incidence in RA patients better than intima-media thickness. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 168.2-168	2.4

24	SAT0037 14-3-3 ETA Sero-Positivity Marks More Severe Disease and Titres Inform Response to Therapy, also in Patients with Lower Crp. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A592.2-A592	2.4
23	Lessons Learned from Disaster Research: The Medical Evaluation of the Disaster in Volendam, The Netherlands. <i>Prehospital and Disaster Medicine</i> , 2005 , 20, 68-68	0.8
22	AB1335-HPR HEALTH PROFESSIONALS' PERSPECTIVE ON THE BENEFITS AND RISKS OF LOW-DOSE GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS [AN INTERNATIONAL SURVEY OF 444 HEALTH PROFESSIONALS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1955.1-1956	2.4
21	AB1223 RHEUMATOID ARTHRITIS PATIENTS INCLUDED IN GLUCOCORTICOID TRIALS MOSTLY RESEMBLE THOSE SEEN IN OBSERVATIONAL COHORTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1903.1-1903	2.4
20	PARE0004 PATIENT PERSPECTIVE ON THE EFFICACY AND RISKS OF GLUCOCORTICOIDS IN RHEUMATOID ARTHRITIS [AN INTERNATIONAL SURVEY OF 1344 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1288.2-1288	2.4
19	THU0614-HPR ASSESSING THE EFFECT OF INTERVENTIONS FOR AXIAL SPONDYLOARTHRITIS ACCORDING TO THE ENDORSED ASAS/OMERACT CORE OUTCOME SET: A META-RESEARCH STUDY OF TRIALS INCLUDED IN COCHRANE REVIEWS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 548.2-550	2.4
18	AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1107.1-1107	2.4
17	POS0197 RESPONSIVENESS OF ULTRASOUND SYNOVITIS AND CLINICAL OUTCOMES IN PSORIATIC ARTHRITIS TREATED WITH SECUKINUMAB: DATA FROM THE ULTIMATE TRIAL. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 314.1-314	2.4
16	OP0226 TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 136-137	2.4
15	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. <i>Trials</i> , 2021 , 22, 406	2.8
14	OP0262 Similar Clinical and Radiological Outcome in The Cobra and Cobra-Light Treatment Group 4 Years after Initiation of The Cobra-Light Trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 157.2-157	2.4
13	Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty. <i>Annals of Internal Medicine</i> , 2019 , 171, 679-680	8
12	Glucocorticoids for rheumatoid arthritis in the era of targeted therapies. <i>Reumatologia Clínica (English Edition)</i> , 2019 , 15, 311-314	0.1
11	Reply. <i>Arthritis Care and Research</i> , 2019 , 71, 577-578	4.7
10	Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e82	2.4
9	Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e125	2.4
8	Response to: Comment on l'Ami titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial' by den Broeder. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e68	2.4
7	More erroneous statements about the use of frequentist statistical methods in medical research. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 122, 4	2.2

- 6 Comment on: Paradoxically protective effect of glucocorticoids on bone mass and fragility fracture in a large cohort: a cross-sectional study. Reply.. *Rheumatology Advances in Practice*, **2022**, 6, rkac011 1.1
- 5 Shoulder and Elbow Pain315-392
- 4 Spondyloarthropathies393-442
- 3 Systemic Sclerosis443-493
- 2 Primary Systemic Vasculitis495-527
- 1 OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology19-24